Neurodivergent travel insurance warning as declarations surge

A rapid increase in holidaymakers declaring neurodivergent conditions such as ADHD and autism to travel insurers is prompting new warnings about disclosure rules, policy gaps and the risk of travelling without valid medical cover.

Data shows ADHD and autism declarations more than doubling

Industry figures reported in specialist travel insurance coverage indicate that UK provider Staysure recorded 4,676 declarations of ADHD and autism among customers aged over 50 between January and July 2026, compared with 2,613 in the whole of 2025. That represents an increase of around 79 percent in just seven months, more than doubling the pace of disclosures year on year.

The spike appears to reflect both rising diagnosis rates in older adults and greater awareness that conditions such as autism and ADHD are commonly treated by insurers as pre existing medical conditions. In practice, this means travellers are frequently required to declare them when buying single trip or annual policies, even when they do not expect the condition to generate a claim.

Separate analysis of medical under declaration by risk and analytics group Verisk points to wider disclosure issues across the travel insurance market. A survey cited in its 2026 report found that about one in four UK customers do not declare all of their medical conditions when purchasing cover, raising the likelihood of claims being refused if undisclosed conditions appear in medical records after an incident abroad.

Consumer research released by Admiral earlier in 2026 adds to the picture of confusion. Nearly one third of respondents said they would not declare weight loss injections prescribed by a doctor, and 16 percent indicated they would not mention ADHD medication when taking out travel insurance, despite insurer guidance that such treatments must be disclosed to keep cover valid.

Disclosure traps for diagnosed and undiagnosed travellers

Publicly available policy documents from mainstream travel insurers show that many treat neurodevelopmental conditions as part of wider mental health or psychiatric categories. Some medical declaration forms explicitly list autism spectrum disorders and attention deficit hyperactivity disorder among conditions that must be disclosed if a traveller has ever been diagnosed, treated or referred for assessment.

The position of people awaiting diagnosis is particularly sensitive. A 2023 announcement from Co op Insurance highlighted that many UK providers would not insure customers with an unconfirmed health status, including those on ADHD or autism waiting lists, because being under investigation for a potential condition can count as a material fact. That leaves some travellers in the paradoxical position that obtaining a formal diagnosis may make securing cover easier than remaining on a long waiting list.

Guidance published by specialists such as Cedartree and Big Cat Travel Insurance illustrates how broad some declarations can be. Online screening tools ask customers to disclose a wide range of pre existing medical conditions, including ADHD and autism, even when these are automatically covered at standard terms. At the same time, policy wording often states that any condition for which a traveller has received treatment, experienced recent symptoms or is awaiting tests must be declared, regardless of whether it seems relevant to the planned trip.

Accounts shared on consumer forums show how easy it is for neurodivergent travellers to fall foul of such wording. Some report discovering only after purchase that being on an autism or ADHD waiting list, or having past notes of anxiety and depression linked to late diagnosis, might need to be disclosed under broad questions about undiagnosed symptoms, psychiatric history or ongoing investigations.

Cover gaps, premium shocks and barriers to booking

Available market research suggests that fully declaring pre existing medical conditions can significantly increase the cost of travel insurance. A 2023 investigation by consumer group Which reported that some medical conditions could push premiums up by more than 1,000 percent in extreme cases, and comparison site data showed that single trip policies cost roughly double on average when any medical condition was disclosed compared with none.

For neurodivergent travellers, the impact is more nuanced. Some insurers, including niche providers focusing on adventure or youth travel, list ADHD among conditions that are automatically covered at standard premiums when stable and not linked to recent hospital treatment. Others require a medical screening questionnaire that may lead to higher prices or restricted options, particularly where multiple mental health, neurological or physical conditions appear together.

In parallel, new products have emerged that market themselves as travel insurance for autism and ADHD. Public information from brokers such as Just Travel Cover describes policies that specifically include cover when these conditions contribute to medical emergencies, missed departures or trip disruption, and that aim to provide clearer wording around neurodevelopmental diagnoses. However, these products can still carry higher premiums than standard cover without declared conditions.

Where travellers decide not to disclose, the financial risk can be substantial. Industry guidance notes that if an insurer discovers undeclared medical information in records obtained during a claim investigation, it may treat the policy as if it never existed and refuse to pay, even when the claim relates to an apparently unrelated incident such as a broken bone or food poisoning.

Confusing rules around mental health and medication

A recurring theme in recent surveys is uncertainty about how far disclosure obligations extend into mental health and routine prescriptions. Admiral’s research found that nearly one in five respondents did not realise that antidepressant use typically needs to be declared, and a similar proportion believed only chronic illnesses count as pre existing conditions. Queries on public forums often show travellers questioning why they must mention autism, ADHD, anxiety or depression when they do not consider these diagnoses relevant to their holiday plans.

Guidance from insurers and travel health organisations indicates that the key issue is stability rather than perceived relevance. Policies frequently define pre existing conditions to include any diagnosed illness, mental health condition or developmental disorder for which a person has seen a doctor, taken prescription medication or been referred to a specialist within a specified look back period, such as two or five years.

This approach also affects travellers carrying stimulant medication for ADHD or using drugs that may be subject to additional import restrictions in some destinations. Independent insurance guides caution that losing or having such medication stolen can create complex claims involving both medical and baggage cover, and may require more detailed documentation than for standard prescriptions. Travellers are therefore advised to check in advance whether replacement costs, emergency consultations and related delays would be covered if their medication is lost abroad.

Student and youth travel advice from health associations similarly notes that attention disorders are common among people studying abroad, and that changes in routine, access to medication or academic pressures can increase the risk of problems during a trip. In that context, comprehensive insurance that recognises and covers existing diagnoses is presented as an important element of pre departure planning.

Calls for clearer questions and neuroinclusive policies

The surge in declarations has prompted renewed debate over how travel insurers frame medical questions and design products for neurodivergent customers. Consumer advocates argue that broad catch all questions about “any psychiatric or psychological disorder” or “any undiagnosed condition under investigation” are difficult to interpret for people managing long histories of overlapping diagnoses, reassessments and waiting list referrals.

Recent commentary in industry journals suggests that more precise, plain language health declarations could reduce accidental non disclosure and improve outcomes for both travellers and insurers. Some providers are experimenting with shorter online questionnaires that explicitly list common neurodevelopmental and mental health conditions, alongside simple explanations of when a condition is considered stable and when travellers should seek additional screening.

There are also early signs of movement toward more inclusive underwriting. Co op’s 2023 decision to expand cover options for people with undiagnosed conditions, including those on ADHD and autism waiting lists, has been presented as an attempt to address a gap affecting hundreds of thousands of potential travellers. A small number of specialist brands now promote customer support teams that are trained in neurodiversity awareness and able to discuss how sensory needs, assistance requirements or support workers fit within policy terms.

Despite these changes, publicly available evidence does not show a coordinated tightening of autism or ADHD rules across the sector. Instead, the data points to uneven practices and patchy understanding of existing requirements. With declarations rising sharply, industry analysts warn that the biggest near term risks lie in the gulf between how insurers phrase their questions and how neurodivergent travellers interpret them when trying to secure straightforward holiday cover.